The Cooper Companies, Inc. (COO) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
COO price how computed
Forward Fair Value verdict
UndervaluedCOO is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $54.37
- Sector
- Healthcare
- 12-month range
- $53.27–$84.32
- Market cap
- $10.3B
- From 52-week high
- -35.5%
- Shares outstanding
- 190M
- Rank in Healthcare by discount to fair value
- #8 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
The Cooper Companies, Inc. manufactures and markets contact lenses, intraocular lenses, and associated products used in vision correction and eye care. The company operates globally, serving customers across North America, Europe, Asia Pacific, and other international markets.
COO currently ranks #8 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $10.3B
- P/E (trailing)
- 12x
- Revenue (TTM)
- $4.24B
- Net margin
- 13.5%
- EPS (TTM)
- $4.61
- Gross margin
- 62.4%
- Debt / equity
- 0.31
- Revenue growth (3-yr avg)
- 5.0%
- Shares outstanding
- 190M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 66 · neutral
- 50-day average
- $63.55
- 200-day average
- $70.04
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2023-07-26)
Earnings how computed
- Next earnings report
- 2026-12-03
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-07 ▲ beat (+3.6%)
2026-04 ▲ beat (+11.0%)
2026-01 ▲ beat (+6.8%)
2025-10 ▲ beat (+3.6%)
2025-07 ▲ beat (+2.8%)
2025-04 ▲ beat (+3.2%)
2025-01 ▲ beat (+1.1%)
2024-10 ▲ beat (+4.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 11 hold · 0 sell (16 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $65.8
- Target vs last price
- +21.0%
What our data shows for COO
- Our model validated 17 trailing price-to-earnings windows for COO, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $53.27–$84.32.
- The 14-day relative strength index sits at a neutral 66.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for COO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent COO news
TickrTrends' derived news-sentiment signal for COO is currently leaning positive, computed from recent coverage.
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO (markets.businessinsider.com, 2026-10-03)
TickrTrends take: The Cooper Companies operates in the Healthcare sector and faces scrutiny from investor counsel regarding a securities class action investigation, which introduces legal and reputational risk factors that valuation models must carefully assess. TickrTrends currently classifies COO as Undervalued, suggesting the market may not yet be fully pricing in the potential financial impact of litigation and associated costs. Investors should monitor how management addresses these legal proceedings and any resulting settlements or judgments, as resolution timelines and expense amounts could materially affect whether the current valuation discount remains justified. - CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal? (insidermonkey.com, 2026-09-24)
TickrTrends take: CooperCompanies' decision to retain CooperSurgical and expand its buyback program suggests management confidence in the company's cash generation and strategic positioning, which aligns with TickrTrends' undervalued assessment. The company's choice to maintain this surgical division rather than divest it indicates management believes it contributes meaningful value, a factor that valuation models may still be underappreciating. For valuation-focused investors, the expanded buyback commitment warrants monitoring to see whether the company can execute capital returns while maintaining adequate investment in its healthcare operations and managing debt levels effectively. - A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain? (insidermonkey.com, 2026-09-21)
TickrTrends take: Cooper Companies experienced a significant stock price decline following an unsuccessful auction process, which has prompted market participants to reassess the company's valuation fundamentals. TickrTrends currently derives an undervalued verdict for COO, suggesting the recent weakness may present an opportunity for value-oriented investors, though the failed auction raises questions about asset quality and strategic direction that warrant careful monitoring. Investors should track whether management can demonstrate operational improvements and capital allocation discipline in the healthcare sector to justify the undervalued assessment.
What people are saying
Follow the COO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for COO show that the Relative Strength Index has moved from the oversold zone into neutral territory this week. The stock remains classified as undervalued based on current valuation metrics within the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is COO stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), COO is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is COO's TickrTrends verdict?
COO's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does COO compare to other Healthcare stocks?
COO ranks #8 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is COO overbought or oversold?
COO's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does COO pay a dividend?
COO has paid no dividend in the last twelve months; its last ex-dividend date on file was 2023-07-26.
When does COO report earnings next?
COO's next earnings report is scheduled for 2026-12-03, per the published earnings calendar.
Does COO usually beat earnings estimates?
Over its last 8 reported quarters COO beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about COO?
Of 16 analysts covering COO, 5 rate it a buy, 11 a hold and 0 a sell - hold-leaning, with a consensus price target of $65.8 (+21.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
COO vs ALGN · COO vs ANIP · COO vs COLL · COO vs DXCM · COO vs EMBC